Citations

Showing 10 of 108152 citations.

Immunohistochemical expression of pituitary tumor transforming gene in pituitary adenomas: clinico‐pathological variables
Salehi, Fateme , Manoranjan, Branavan , Scheithauer, Bernd W., Lloyd, Ricardo V., Kalman, Kovacs, Cusimano, Michael D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.925.8 Get It

Pituitary tumor transforming gene (PTTG) was initially found to be overexpressed in GH4 rat pituitary adenomas (PA). PTTG overexpression has been correlated with patient survival, tumor grade, and/or invasiveness in several tumors including those of thyroid, breast, lung, and colon. Studies of PTTG as a prognostic indicator in PAs are limited and show conflicting results. We investigated PTTG immunostaining in 79 PAs of different subtypes (growth hormone (GH), 12; prolactin (PRL), 6, adrenocorticotropic hormone (ACTH), 11, gonadotroph, 21; null cell, 29) in relation to clinico‐pathological variables including patient age and sex, as well as tumor size, and invasiveness. The streptavidin‐biotin‐peroxidase method was used, with a monoclonal PTTG antibody (Abcam, Cambridge, UK). PTTG expression was found to be cytoplasmic in all PAs, with highest levels being present in GH adenomas and lowest in the PRL ones. No correlation was found with patient age, sex, tumor size or invasiveness. Thus, it appears that PTTG cannot serve as a prognostic marker in patients with PAs. PTTG has been implicated in several tumorigenic processes including angiogenesis, DNA damage repair and invasiveness. PTTG overexpression in PA warrants further research into its role in PA initiation and progression.
Corrigendum to “Clinical Outcomes of Critically Ill Patients Using Inhaled Nitric Oxide (iNO) during Intrahospital Transport”
Koyfman, Leonid, Simchon, Omri, Koyfman, Anna , Moshinsky, Shoshana, Gruenbaum, Benjamin F. , Gal, Ron, Friger, Michael , Arotsker, Natan, Klein, Moti, Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick, Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

Critical Care Research and Practice | June 21, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-1

10.1155/2021/9794018 | PMID 34249376 Get It

Contribution of Estrogen receptor β (ERβ) on platelet mitochondrial function and microparticle production in aged female mice
Jayachandran, Muthuvel , Jahangir, Arshad , Owen, Whyte G., Miller, Virginia M. , Preston, Claudia C. , Hunter, Larry W. , Korach, Kenneth Steven

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.988.2 Get It

Estrogen receptor beta (βER) is present in platelets but little is known about how βER contributes to platelet physiology. Platelet mitochondrial function and circulating platelet‐derived microparticles were analyzed in aged (24 months old) female wild type (WT) and estrogen receptor beta knockout (βERKO) mice. In intact, unstimulated platelets, ERβ did not co‐localized with mitochondria. Platelet lactate production, mitochondrial membrane potential and superoxide generation were similar in both groups, but activities of cytochrome bc 1 and cytochrome c oxidase were significantly less (P<0.05) in platelets of βERKO mice. Total numbers of platelet‐derived microparticles and those positive for procoagulant phosphatidylserine (PS) were two to three times higher (P<0.05) in βERKO than WT mice. Greater than 40% of procoagulant microparticles were derived from cells other than platelets in both groups of mice. Thrombin generating capacity of microvesicles was also greater in βERKO mice. Thus, loss of βER leads to significant changes in activities of enzymes of the mitochondrial electron transport system, and to increases in circulating procoagulant microparticles which may contribute to an increased thrombotic risk with aging in persons with βER gene polymorphisms. This study is supported by HL78638, AHA30503Z and Mayo Foundation.
Mechanisms Underlying Mechanical Dysfunction After Rewarming From Hypothermia
Tveita, Torkjel , Han, Young‐Soo , Prakash, Y. S. , Sieck, Gary C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.953.14 Get It

Rewarming patients following profound hypothermia may result in acute heart failure and high mortality (50‐80%); however underlying pathophysiological mechanisms are largely unknown. We characterized myocardial dysfunction induced by hypothermia/rewarming (H/R) by measuring intracellular Ca 2+ concentration ([Ca 2+ ] i ) and twitch force in intact electrically stimulated left ventricular (LV) rat papillary muscles loaded with Fura‐2AM. In skinned papillary muscle fibers, we assessed maximal Ca 2+ ‐activated force (F max ) and Ca 2+ sensitivity of force. Following H/R, peak twitch force decreased by 30‐40%, but [Ca 2+ ] i was not significantly altered. In skinned preparations, maximal F max was decreased by ~30%, while the pCa required for 50% of F max (pCa 50 ) was reduced by ~0.14. Interestingly, in rewarmed papillary muscle, both total cTnI phosphorylation and protein kinase A (PKA)‐mediated cTnI phosphorylation at Ser23/24 were significantly increased compared to controls. We conclude that after H/R myocardial contractility is significantly reduced as evidenced by reduced twitch force and F max . Reduced myocardial contractility is attributed to decreased Ca 2+ sensitivity of force that likely results from increased cTnI phosphorylation.
Cyclic GMP stimulating actions of a novel fully humanized designer natriuretic peptide, CBB‐NP, in human aortic endothelial cells as compared to the native natriuretic peptides
Lee, Candace Y.W., Huntley, Brenda K., Burnett, John C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.932.10 Get It

Background CBB‐NP is a novel fully humanized designer natriuretic peptide (NP) integrating the 17‐amino‐acid ring of human C‐type NP (CNP) with the N‐ and the C‐termini of human B‐type NP (BNP). CBB‐NP exerted natriuretic, diuretic, renal‐preserving and cardiac‐unloading actions in anesthetized dogs. In this investigation, we compared for the first time the cGMP stimulating actions of CBB‐NP vs human atrial NP (ANP), BNP and CNP in human aortic endothelial cells (HAEC). Methods CBB‐NP was synthesized (SPKMVQGSGCFGLKLDRIGSMSGLGCKVLRRH with a disulfide bond joining the C residues). HAEC were incubated with ANP, BNP, CNP or CBB‐NP for 10 min (10 −6 M). Cyclic GMP was quantified by RIA. Results CBB‐NP and CNP increased cGMP (pmol/mL) vs control (0.108±0.020 and 0.174±0.036 vs 0.001±0.001, P<0.01 and <0.001, respectively). CBB‐NP elicited a greater cGMP response vs ANP (0.027±0.002, P<0.05), whereas comparable responses were observed vs BNP and CNP. When the native NPs were compared, a greater cGMP stimulating response was detected with CNP vs ANP and BNP (P<0.001 and <0.01, respectively). Conclusions The novel designer NP, CBB‐NP, stimulates cGMP in human aortic endothelial cells to a comparable extent as compared to the native BNP and CNP. Moreover, its cGMP stimulating action is greater than that of ANP. The therapeutic potential of CBB‐NP in models of cardiovascular diseases warrants further investigation. Supported by NIH, HFSA and ASCPT
+ACA BRCA1 promoter polymorphism genotypic frequency among unaffected individuals and breast disease patients
White, Kristen , Basta, Patricia V. , Booker, Jessica K., Highsmith, W. Edward, Tsongalis, Gregory J. , Millikan, Robert C., Coleman, William B.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.925.9 Get It

We previously identified a +ACA polymorphism at ‐600 bp in the BRCA1 promoter that creates a FAC1 transcriptional repressor binding site. Subsequently, we performed a genotyping study to determine the prevalence of this BRCA1 promoter polymorphism among unaffected individuals and patients with breast disease. The genotypic distribution of the BRCA1 promoter was determined for 997 unaffected individuals and 763 patients with breast disease from the Mayo Clinic, UNC Hospitals, and the Carolina Breast Cancer Study. The BRCA1 promoter genotypic frequency among unaffected individuals was 481/997 (48%) WT/WT, 432/997 (43%) WT/ACA, and 91/997 (9%) ACA/ACA. The BRCA1 promoter genotypic frequency among patients with breast disease was 348/763 (46%) WT/WT, 343/763 (45%) WT/ACA, and 72/763 (9%) ACA/ACA. No differences were noted in the genotypic distribution of the BRCA1 promoter among patients with DCIS, BRCA1 mutation, suspected BRCA1‐related cancer (BRCAx), or sporadic breast cancer. The allelic frequency of the +ACA BRCA1 promoter polymorphism among breast disease groups [343/415 (83%) WT/ACA and 72/415 (17%) ACA/ACA] were not different than the allelic frequency of the controls [432/523 (83%) WT/ACA and 91/523 (17%) ACA/ACA]. Our results suggest that the +ACA BRCA1 promoter polymorphism occurs commonly, and may contribute to breast cancer upon activation of the FAC1 repressor protein. Support: NIH CA78343.
Immunohistochemical expression of estrogen receptor α and β in pituitary adenomas
Manoranjan, Branavan , Salehi, Fateme , Scheithauer, Bernd W., Rotondo, Fabio , Kovács, Kálmán , Cusimano, Michael D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.925.10 Get It

Estrogen is involved in pituitary tumorigenesis, acting through estrogen receptors alpha (ERα) and beta (ERβ). Our study investigated the prognostic value of ERα/ERβ as markers in pituitary adenomas. Tissue samples and clinico‐pathological data (patient age and sex, tumor size, invasiveness and recurrence) were obtained from 78 patients with pituitary adenomas. Immunohistochemistry was performed using the streptavidin‐biotin‐peroxidase complex method. A monoclonal and polyclonal antibody were used for ERα and ERβ expression respectively. Intensity of ERα/ERβ expression was evaluated using a scale of 0 to 3. Percentage of positive cells was evaluated on a scale of 0 to 4. ERα immunopositivity was evident in 40 of 78 cases (51%), while ERβ stained positive in 49 of 78 cases (63%). No correlation was found between ERβ expression and pituitary tumor cell types or clinico‐pathological factors. A significant difference was present in ERα expression between different tumor types. ERα positivity was present to a greater extent in macroadenomas. This finding supports the role of ERα in tumor growth and progression. Elevated ERα positivity and intensity were also found in non‐invasive adenomas. It appears that ERα may be a valuable biological marker for tumor size and invasiveness, while ERβ is a poor marker. The role of ERα expression in pituitary tumor initiation and progression warrants further investigation.
Glycemic response of type 2 diabetics to sweetened dried cranberries
Wilson, Ted, Morcomb, Erin F., Schmidt, Travis P., Luebke, Justin L., Carrell, Emily J., Leveranz, Megan C., Kobs, Lisa, Vorsa, Nicholi , Singh, Ajay , Limburg, Paul J.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.900.6 Get It

Diabetics tend to have inadequate fruit consumption, elevated plasma glucose and insulin, and increased cardiovascular disease risk. Dried fruit may represent one way to increase fruit consumption among diabetics. Polydextrose is a commonly used soluble fiber and bulking agent providing very little available carbohydrate energy. The glycemic and insulinemic response of type 2 diabetics (n=13) to a single serving of white bread (57g; 160 Cal; 1 g fiber), raw cranberries (RC; 55g; 21 Cal; 1 g fiber), sweetened dried cranberries‐original (SCDO; 40g, 138 Cal; 2.1g fiber), and SDC‐less sugar (SDCLS; 40g; 113 Cal; 1.8g fiber + 10g polydextrose) was measured in a single cross‐over design. Plasma glucose (mg/dl) and insulin ( μU/ml) was measured prior to consumption, then 30, 60 and 120 minutes postprandially. Plasma glucose peaked at 30 or 60 min following bread, RC, SDCO, and SDCLS at 175 ± 10, 127 ± 7, 175 ± 10 and 158 ± 9 min, respectively, and remained significantly elevated 120 min following bread consumption. Peak plasma insulin for SDCO (15 ± 2) and RC (10 ± 1) was significantly less than bread (22 ± 2) or SDCO (22 ± 4), and remained slightly elevated at 120 minutes. The area under the curve values reflected similar changes. SDCLS consumption could be useful for improving fruit consumption by type 2 diabetics in a manner that provides glycemic and insulinemic benefits. Sponsor: Ocean Spray Cranberries Inc.
Biofilm formation by biologic nanoparticles may require extracellular RNA and intact ribosomal function
Schwartz, Maria A K, Miller, Virginia M. , Schwartz, Maria K., Hunter, Larry W. , Lieske, John C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.817.8 Get It

Biologic nanoparticles (NPs) isolated from human arterial calcifications and kidney stones form an adherent film on the bottom of flasks when placed in standard cell culture conditions. Since NPs have certain features consistent with microorganisms, we hypothesized that antibiotics and/or RNAse might inhibit this biofilm formation. NPs isolated from calcified human arterial tissue were cultured onto glass coverslips in 24‐well plates containing DMEM with 10% fetal calf serum, plus either no treatment (control), RNase, tetracycline or gentamicin. At 1, 7 and 14 days after inoculation, coverslips were fixed, mounted, and analyzed using a CytoViva darkfield scope and KS‐400 imaging software. In control wells, the percent coverslip covered by biofilm increased by 120% from day 1 to day 14, compared to 47% and 35% in wells treated with RNase and gentamicin, respectively. Wells treated with tetracycline showed a 3% decrease in biofilm by day 14. Since RNase should not enter intact cells, these results indicate that extracellular RNA may play a role in biofilm formation by NPs. Although tetracycline can chelate calcium, it also inhibits ribosomal function, as does gentamicin. Therefore these results also suggest that intact ribosomal function is required for NP‐associated biofilm growth. These experiments suggest that biofilm formation by NPs consists of biological as well as physicochemical processes.
Lipopolysaccharide‐induced inflammation reduces tyrosine phosphorylation of cardiac connexin 43
Ouellette, Yves , Sieck, Gary C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.805.14 Get It

Myocardial performance is depressed in both sepsis and endotoxin shock. Altered gap junctional coupling of ventricular myocytes may play an important role in myocardial dysfunction during sepsis. Since phosphorylation is known to regulate turnover of gap junction protein, we hypothesized that the phosphorylation status of connexin 43 (Cx43) is altered in vivo following exposure to lipopolysacccharide (LPS). Saline or LPS (25 mg/kg; E. coli 055:B5) was injected intraperitoneally into c57bl/6 mice. At 18 h, hearts were excised and snap frozen on dry ice. Tissue was homogenized in Triton X‐100 lysate buffer, centrifuged and prepared for Western blot. Cx43 was immunoprecipitated from the supernatant and tyrosine phosphorylation of Cx43, detected by immunoblot. Phosphorylated forms of Cx43 are seen as three major bands on Western blots. After LPS treatment, there is a decrease in the intensity of the fastest migrating band (Cx43‐P0) and an increase in the two slower migrating forms, (Cx43‐P1 and Cx43‐P2). This corresponds to a decrease in tyrosine phosphorylation of Cx43. LPS results in decrease in myocardial Cx43 tyrosine phosphorylation possibly mediating LPS‐induced myocardial dysfunction.